Summary by Moomoo AI
Hansen Pharmaceuticals announced on November 28, 2024 that its four innovative medicines have been successfully renewed to the 2024 National Health Insurance Catalog, which will be officially implemented on January 1, 2025. The four drugs, which include Amethinic Thesulfate Tablets, Fluormatinic Acid Tablets, Ineryl Bead Single Injection, and Polyethylene Glycerate Injection, are targeted at patients with non-small cell lung cancer, chronic myeloid leukemia, neuromyelitis spectrum disease, and diabetes. This move will further enhance the affordability and accessibility of these innovative drugs among patients.In addition, other innovative medicines from Hanssen Pharmaceuticals, such as pemosapeptide injections and amitinofovir tablets, have been included in the 2023 National Health Catalogue. The agreement is valid until December 31, 2025; Morphinitazole Sodium Chloride Injection has been included in the National Health Directory...Show More